Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.

about

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.

Item

http://www.wikidata.org/entity/Q54114243

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@en

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@nl

type

Item

label

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@en

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@nl

prefLabel

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@en

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@nl

P1476

Genetic Association of Drug Re ...... all Cell Lung Cancer Patients.

@en

P2093

Cong Wang

http://www.w3.org/2001/XMLSchema#string

Fang Chen

http://www.w3.org/2001/XMLSchema#string

Huihui Du

http://www.w3.org/2001/XMLSchema#string

Jingsong Ma

http://www.w3.org/2001/XMLSchema#string

Liang Guo

http://www.w3.org/2001/XMLSchema#string

Lin He

http://www.w3.org/2001/XMLSchema#string

Lu Shen

http://www.w3.org/2001/XMLSchema#string

Mo Li

http://www.w3.org/2001/XMLSchema#string

Qingqing Xu

http://www.w3.org/2001/XMLSchema#string

Shengying Qin

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Global cancer statistics

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Global cancer statistics, 2012

Cancer statistics, 2013

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Mutational analysis of the tyrosine kinome in colorectal cancers

KRAS mutations in non-small cell lung cancer

P304

360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2018.00360

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29695969

http://www.w3.org/2001/XMLSchema#string

P932

5904969

http://www.w3.org/2001/XMLSchema#string